Abstract:In the latest National Comprehensive Cancer Network guideline for NSCLC, pembrolizumab is recommended as preferred first-line therapy of nonsquamous NSCLC patients with programmed death ligand 1 (PD-L1) expression positive (≥50%) and no EGFR, ALK receptor tyrosine kinase (ALK) genomic aberrations. However, not all PD-L1–positive patients can respond to immune checkpoint inhibitors (ICIs). Based upon the categorization of tumor immunity in the microenvironment into four distinct types clarified by Kim et al.,1Kim T.K. Herbst R.S. Chen L. Defining and understanding adaptive resistance in cancer immunotherapy.Trends Immunol. 2018; 39: 624-631Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar the expression of PD-L1 is only one of the elements of successful immune checkpoint blockade (ICB) treatment and the presence of tumor infiltrating lymphocytes (TILs) is indispensable to anti–programmed death 1 (PD-1) therapy as well. Recent research has shown that the highest CD8 T cell density was observed in those lung adenocarcinoma patients who harbored tumor protein p53 (TP53) mutations without co-existence of serine/threonine kinase 11 (STK11) or EGFR mutations benefited from PD-1 blockade more remarkably.2Biton J. Mansuet-Lupo A. Pécuchet N. et al.TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti–PD-1 in lung adenocarcinoma.Clin Cancer Res. 2018; 24: 5710-5723Crossref PubMed Scopus (179) Google Scholar Notwithstanding, we encountered a Chinese lung adenocarcinoma patient who had a strong expression of PD-L1 (≥90%) along with TP53 mutation without EGFR/STK11 alterations but who did not respond to pembrolizumab; this patient exhibited hyperprogressive disease (HPD) after immunotherapy. To explore what is responsible for this HPD, whole-exome sequencing, targeted sequencing, multiplex immunohistochemistry (mIHC), and HLA typing assay were used to examine his genomic features and tumor immunity in the microenvironment signature. At the end of May 2017, a 65-year-old man presenting with hemoptysis for 2 months was taken to hospital for treatment. Positron-emission tomography–computed tomography (CT) scan revealed abnormal increased intake of 18F-flurodeoxyglucose in the inferior lobe of the right lung and several enlarged mediastinal lymph nodes. Then he underwent right lower lobectomy and was diagnosed with a T3N2M0, stage IIIa, poorly differentiated lung adenocarcinoma (Fig. 1A). The resected tumor specimens were detected by a 61-gene panel (unknown genetic-testing company). Only two pathogenic mutations, BRAF p.G469V (24.24%) and TP53 p.R337L (41.76%) were identified. Approximately 25 days after surgery, follow-up magnetic resonance imaging results showed new metastasis in his right frontal lobe with severe edema around the tumor (Fig. 1B). In the next 4 months, he underwent radiotherapy (60 Gy in 20 times) for 1 month and four cycles of chemotherapy (pemetrexed plus nedaplatin) for 3 months, and there was a clear shrinkage of brain lesions. Nonetheless, 5 months after surgery, his chest CT scan revealed new multiple bilateral lung nodules. Previously, a PD-L1 assay (SP142 staining) of his surgical tumor tissue had been performed. The expression level of PD-L1 was up to 98% (Fig. 1C). Based on such high expression of PD-L1 without other actionable alterations, he received pembrolizumab (150 mg, 2 mg/kg) combined with paclitaxel liposome for two cycles. Unfortunately, 1.5 months after initiation of pembrolizumab, he began to experience multiple dysfunction of central nervous system including loss of memory, aphasia, and disorient. Both chest CT scan and encephalic magnetic resonance imaging confirmed a rapid progression in his lung along with brain (Fig. 1B). Thereafter, his needle pulmonary biopsy sample obtained after exposure to pembrolizumab was sent for a second PD-L1 (SP142) assay and next-generation sequencing test, targeting all exons or hotspots of 465 cancer-related genes at a College of American Pathologists–certified laboratory (GeneCast Biotechnology Co., Beijing). It is noteworthy that in addition to preceding BRAF/TP53 mutations, MET amplification (4.8×) was detected in this test (Fig. 2A) whereas no copy number variation of MNNG HOS transforming gene (MET) was reported in the last 61-gene panel test. Besides, there was still an extremely high expression level of PD-L1 (90%) in the recurrent tumor (Fig. 1C). In February 2018, this patient started treatment with oral c-MET inhibitor crizotinib. One month later, he complained that anhelation was alleviated markedly. Chest CT scan displayed a significant regression of bilateral lung nodules and right hilar lymph nodes compared with that before administration with crizotinib (Fig. 1B). After following 2 months of crizotinib treatment, he exhibited sustained partial response according to Response Evaluation Criteria in Solid Tumors version 1.1 criteria and continued this targeted therapy for 5 months. His condition remains stable.Figure 2Genomic alterations and multiplex immunohistochemistry (mIHC) results of tumor specimens from this patient. A, Copy number variations of MET, MDM2, CDK4, CDK6, and (B) two shared pathogenic mutations in his primary and recurrent lesions. C, Representative images of PanCK (pan cytokeratin), CD3, CD8, PD-1, and CD19 shown by mIHC in resected tumor tissues. Nuclei (blue) were counter-stained by DAPI. Original magnification ×200. D, Quantification results of mIHC from 15 random vision fields.View Large Image Figure ViewerDownload Hi-res image Download (PPT) In light of the criterion of HPD described before, this patient’s worse outcome after immunotherapy can be measured as HPD.3Kato S. Goodman A. Walavalkar V. et al.Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate.Clin Cancer Res. 2017; 23: 4242-4250Crossref PubMed Scopus (574) Google Scholar Whole-exome sequencing results revealed MET amplification (4×) along with above two somatic mutations BRAF p.G469V (20%) and TP53 p.R337L (32%) in his primary cancer (Fig. 2A and B). Additionally, copy number alterations of MDM2, CDK4, and CDK6 were detected in primary tumor as well as recurrent lesions (Fig. 2A). Despite the potential involvement of MDM2/4 amplification in HPD caused by anti–PD-1 therapy, there was no high-level amplification of MDM2 in this case, which seems to be insufficient to explain this HPD.3Kato S. Goodman A. Walavalkar V. et al.Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate.Clin Cancer Res. 2017; 23: 4242-4250Crossref PubMed Scopus (574) Google Scholar, 4Fuentes-Antrás J. Provencio M. Díaz-Rubio E. Hyperprogression as a distinct outcome after immunotherapy.Cancer Treat Rev. 2018; 70: 16-21Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar Importantly, there is inconsistent evidence about predicting HPD by MDM2/4 amplification. According to Rizvi et al.,5Rizvi H. Sanchez-Vega F. La K. et al.molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing.J Clin Oncol. 2018; 36: 633-641Crossref PubMed Scopus (823) Google Scholar progression-free survival of those NSCLC patients with amplifications in MDM2/4 was not mainly different from that of overall patients.5Rizvi H. Sanchez-Vega F. La K. et al.molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing.J Clin Oncol. 2018; 36: 633-641Crossref PubMed Scopus (823) Google Scholar In addition, CDK4/6 amplification or overexpression is believed to be closely related to tumorigenesis.6Choi Y.J. Li X. Hydbring P. et al.The requirement for cyclin D function in tumor maintenance.Cancer Cell. 2012; 22: 438-451Abstract Full Text Full Text PDF PubMed Scopus (247) Google Scholar Furthermore, CDK4/6 inhibition was reported to be capable of inducing antitumor immunity through enhancing tumor antigen presentation and suppressing regulatory T cells.7Goel S. DeCristo M.J. Watt A.C. et al.CDK4/6 inhibition triggers anti-tumour immunity.Nature. 2017; 548: 471-475Crossref PubMed Scopus (728) Google Scholar However, little attention has been paid to the role of copy number variation of CDK4/6 in resistance to ICIs or HPD of immunotherapy so far. A most confusing problem of this case is why he harbored such strong PD-L1 expression as well as high frequency of TP53 mutation without EGFR/STK11 alterations but was refractory to anti–PD-1 antibody pembrolizumab. We examined the immune microenvironment of his primary lesions by mIHC and found that there were rather low degrees of infiltration of CD3+/CD8+ lymphocytes as shown in Figure 2C. Quantitative analysis revealed that the percentages of CD8+ and CD3+ TILs in tumor region, stroma region, and whole region were 0.26%, 1.39%, and 0.62% along with 1.27%, 3.87%, and 2.11%, respectively (Fig. 2D). Despite not having enough specimens of recurrent lesions to perform mIHC, it was shown that extremely few lymphocytes were present in the PD-L1 assay (Fig. 1C). On the basis of the principles of ICB treatment, lack of CD8+ TILs is likely responsible for his nonresponse to pembrolizumab, but it perhaps cannot fully illuminate the reason for developing HPD.1Kim T.K. Herbst R.S. Chen L. Defining and understanding adaptive resistance in cancer immunotherapy.Trends Immunol. 2018; 39: 624-631Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar Finally, we performed validated HLA typing assay of this individual’s DNA from peripheral blood cells. Chowell et al.8Chowell D. Morris L.G.T. Grigg C.M. et al.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.Science. 2018; 359: 582-587Crossref PubMed Scopus (579) Google Scholar discovered that ICB-treated melanoma patients with HLA-B*15:01 allele of HLA-B62 supertype had poor outcomes.8Chowell D. Morris L.G.T. Grigg C.M. et al.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.Science. 2018; 359: 582-587Crossref PubMed Scopus (579) Google Scholar Herein, both of classical HLA-I loci of this patient are listed in Table 1. Notably, he has two different germline alleles (HLA-B*15:01 and HLA-B*15:02) of HLA-B62 supertype; that is, it is “homozygosity” for the HLA-B62 supertype. Molecular dynamics simulations showed that the structural feature and dynamical factors of HLA-B*15:01 protein likely impair its affinity with peptide for effective neoantigen presentation, which is possibly linked to its negative impact on ICB-treated patients’ survival.8Chowell D. Morris L.G.T. Grigg C.M. et al.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.Science. 2018; 359: 582-587Crossref PubMed Scopus (579) Google Scholar Theoretically, the HLA-B*15:02 protein might have the same or similar property as HLA-B*15:01 for interaction with antigen peptide. Given this, it may have dual influence upon the cancer-immunity cycle. For one thing, HLA-I genotype-caused weak capacity for antigen presentation in antigen-presenting cells goes against priming and activation of T cells in lymph nodes near tumor lesions. For another, cancer cells take advantage of reduced self-antigen presentation by HLA-I molecules to escape being recognized and attacked by CD8+ TILs. The synergy effects from above two aspects probably involved in scanty CD8+ and CD3+ TILs along with poor response to pembrolizumab in this patient, although his somatic mutation profile was actually in favor of T cell infiltration.Table 1Classical HLA Class I Genotype of the PatientHLA Class IHLA Class I AllelesHeterozygosityHLA Class I SupertypesHLA-AA*11:01 A*24:02YesA03 A24HLA-BB*15:01 B*15:02YesB62 B62HLA-CC*01:02 C*08:01YesNA NA Open table in a new tab With respect to the predictive value of HLA in ICB treatment, we believe that the HLA-I genotype is perhaps not suitable to be used as an independent biomarker for NSCLC, but it can be integrated with other biomarkers to better understand clinical outcome of NSCLC patients receiving PD-1/PD-L1 inhibitors. To date, the exact molecular mechanisms behind HPD of immunotherapy are still poorly understood. In one sense, HPD is a special type of primary resistance to ICB treatment. Briefly, because of a lack of TILs or the defects associated with cancer-immunity response or immunosuppressive microenvironment, ICIs do not always take effect, that is, there is resistance. Cancer cells are generally governed by some key deregulated signaling pathways or pathogenic genomic alterations. Immune checkpoint-mediated immunosuppression is also a deregulated mechanism facilitating tumor growth. When the PD-1/PD-L1 axis is blockaded by ICIs, other innate pro-survival pathways of cancer cells are prone to be aberrantly activated and certain cell subsets with specific driver mutations might gain growth advantage. Under the circumstances, if antitumor activity of TILs restored by ICB is insufficient to cope with such kind of cancer cells, the accelerated tumor growth or rapid progression likely occurs, that is, HPD. As evidenced by the fact that those NSCLC patients with driving EGFR alterations usually have worse outcome after undergoing anti–PD-1 therapy, it is plausible that MET amplification, another important driving alteration of NSCLC, participates in the pathologic process of primary resistance to pembrolizumab, even HPD in this patient3Kato S. Goodman A. Walavalkar V. et al.Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate.Clin Cancer Res. 2017; 23: 4242-4250Crossref PubMed Scopus (574) Google Scholar, 9Gainor J.F. Shaw A.T. Sequist L.V. et al.EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non–small cell lung cancer: a retrospective analysis.Clin Cancer Res. 2016; 22: 4585-4593Crossref PubMed Scopus (816) Google Scholar Collectively, MET amplification may cooperate with low-level infiltration of CD8+ T cells potentially related to HLA-B62 supertype to result in HPD of this patient after ICB treatment. This study was granted by the National Key Sci-Tech Special Project of China (No. 2018ZX10302207).

Abstract:Despite the prominent advancements of tyrosine kinase inhibitors (TKIs) in patients with metastatic EGFR-mutant NSCLC, acquired resistance remains an insurmountable obstacle.1Wu S.G. Shih J.Y. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.Mol Cancer. 2018; 17: 38Crossref PubMed Scopus (218) Google Scholar At present, cytotoxic chemotherapy is the most common subsequent anticancer therapy after the discontinuation of third-generation EGFR TKI (osimertinib) treatment, the state-of-the-art EGFR TKI in current clinical practice.2Ramalingam S.S. Vansteenkiste J. Planchard D. et al.Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC.N Engl J Med. 2020; 382: 41-50Crossref PubMed Scopus (660) Google Scholar Nevertheless, chemotherapy has limited long-term survival benefits and the efficacy is far from satisfactory. Therefore, developing novel therapeutic strategies to boost the efficacy is in high demand. Immune checkpoint blockade targeting programmed cell death protein-1 and programmed death ligand-1 (PD-L1) represents another breakthrough in cancer therapy in the past decade.3Melero I. Berman D.M. Aznar M.A. Korman A.J. Pérez Gracia J.L. Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer.Nat Rev Cancer. 2015; 15: 457-472Crossref PubMed Scopus (443) Google Scholar Nevertheless, even the sun has its dark side. The beneficial patient populations seem not to overlap with those who benefit from EGFR TKIs. Immune checkpoint inhibitors (ICIs), either as monotherapy or in combination with chemotherapy, have been advocated as the standard of care for patients with metastatic NSCLC whose tumors do not harbor EGFR and ALK alterations.4Zhou F. Qiao M. Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer.Cell Mol Immunol. 2021; 18: 279-293Crossref PubMed Scopus (10) Google Scholar Being amazed at the dramatic and durable responses in some cases, integrating ICIs into the treatment course of patients with EGFR-mutant NSCLC has attracted extensive attention. In the current issue of controversies in thoracic oncology, we here argue for ICIs to be combined with chemotherapy in the treatment of patients with stage IV EGFR-mutant NSCLC whose disease has progressed on all available TKIs. Here, we are kind to remind our readers that the theory “ICIs should not be used in patients with EGFR-mutant NSCLC” is based on the results of ICI monotherapy from several retrospective studies.5Hastings K. Yu H.A. Wei W. et al.EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.Ann Oncol. 2019; 30: 1311-1320Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar,6Garassino M.C. Gelibter A.J. Grossi F. et al.Italian nivolumab expanded access program in nonsquamous non-small cell lung cancer patients: results in never-smokers and EGFR-mutant patients.J Thorac Oncol. 2018; 13: 1146-1155Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar Because of limited patients with EGFR-mutant advanced NSCLC enrolling in the prospective studies, two pooled meta-analyses compared ICI monotherapy with docetaxel as second-line therapy and found no overall survival (OS) benefits in patients who received ICI monotherapy.7Lee C.K. Man J. Lord S. et al.Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis.J Thorac Oncol. 2017; 12: 403-407Abstract Full Text Full Text PDF PubMed Scopus (456) Google Scholar Notably, the sample size of the included patients with EGFR-mutant NSCLC was still small (n = 186 and n = 271 in these two meta-analyses) and these two meta-analyses were not performed on the basis of individual patient data.7Lee C.K. Man J. Lord S. et al.Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis.J Thorac Oncol. 2017; 12: 403-407Abstract Full Text Full Text PDF PubMed Scopus (456) Google Scholar,8Lee C.K. Man J. Lord S. et al.Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis.JAMA Oncol. 2018; 4: 210-216Crossref PubMed Scopus (259) Google Scholar ATLANTIC was the first prospective study that evaluated the efficacy of durvalumab in patients with oncogene-driven advanced NSCLC with disease progression after at least two previous systemic regimens.9Garassino M.C. Cho B.C. Kim J.H. et al.Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Lancet Oncol. 2018; 19: 521-536Abstract Full Text Full Text PDF PubMed Scopus (306) Google Scholar Specifically, cohort I enrolled 111 patients with EGFR or ALK-positive tumors after failure on previous TKI therapy. Although objective response rates (ORRs) were not encouraging (12.2% in PD-L1 expression ≥ 25% patients),9Garassino M.C. Cho B.C. Kim J.H. et al.Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Lancet Oncol. 2018; 19: 521-536Abstract Full Text Full Text PDF PubMed Scopus (306) Google Scholar long-term survival benefits were observed in some patients on account of the final OS analysis.10Garassino M.C. Cho B.C. Kim J.H. et al.Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: the phase II ATLANTIC study.Lung Cancer. 2020; 147: 137-142Abstract Full Text Full Text PDF PubMed Scopus (12) Google Scholar The 2-year OS rate was 40.7% in patients with EGFR or ALK-positive tumors and PD-L1 expression greater than or equal to 25% tumors, whereas it was 24.2% in patients with EGFR and ALK-negative tumors and PD-L1 expression greater than or equal to 25% tumors.10Garassino M.C. Cho B.C. Kim J.H. et al.Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: the phase II ATLANTIC study.Lung Cancer. 2020; 147: 137-142Abstract Full Text Full Text PDF PubMed Scopus (12) Google Scholar The median OS was 13.3 months and 10.9 months, respectively, suggesting the OS of patients with EGFR or ALK-positive tumors was at least not inferior to that of patients with EGFR and ALK-negative tumors when receiving durvalumab monotherapy. Notably, an exploratory analysis revealed that patients with EGFR-mutant and PD-L1 greater than or equal to 25% had a median OS of 16.1 months.10Garassino M.C. Cho B.C. Kim J.H. et al.Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: the phase II ATLANTIC study.Lung Cancer. 2020; 147: 137-142Abstract Full Text Full Text PDF PubMed Scopus (12) Google Scholar These results supported the activity of durvalumab in patients with previously pretreated, EGFR-mutant advanced NSCLC whose disease has progressed on TKI therapy. The combination of ICIs and chemotherapy, the current debate issue, has been a standard of care in patients with advanced NSCLC lacking EGFR-sensitizing mutations.4Zhou F. Qiao M. Zhou C. The cutting-edge progress of immune-checkpoint blockade in lung cancer.Cell Mol Immunol. 2021; 18: 279-293Crossref PubMed Scopus (10) Google Scholar The role of this therapeutic strategy in EGFR-mutant NSCLC is still controversial because patients with EGFR-mutant NSCLC are usually excluded from previous studies.11Gadgeel S. Rodríguez-Abreu D. Speranza G. et al.Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer.J Clin Oncol. 2020; 38: 1505-1517Crossref PubMed Scopus (242) Google Scholar IMpower150 was a phase 3 study that compared atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) and atezolizumab, carboplatin, and paclitaxel (ACP) with bevacizumab, carboplatin, and paclitaxel (BCP) in patients with nonsquamous metastatic NSCLC. Notably, this trial enrolled 124 patients with EGFR-mutant NSCLC. In this key subgroup analysis, ABCP prolonged progression-free survival (PFS) (10.3 versus 6.1 mo; hazard ratio, 0.41, 95% confidence interval: 0.23–0.75) and OS (29.4 versus 18.1 mo; hazard ratio, 0.60, 95% confidence interval: 0.31–1.14) compared with BCP alone in patients with EGFR-sensitizing mutations,12Reck M. Mok T.S.K. Nishio M. et al.Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.Lancet Respir Med. 2019; 7: 387-401Abstract Full Text Full Text PDF PubMed Scopus (368) Google Scholar,13Reck M. Mok T. Socinski M.A. et al.1293P IMpower150: updated efficacy analysis in patients with EGFR mutations.Ann Oncol. 2020; 31: S837-S838Abstract Full Text Full Text PDF Google Scholar supporting ABCP regimen as an option for patients with EGFR mutations whose disease has progressed on previous TKIs. A recent phase 2 PROLUNG study that compared pembrolizumab plus docetaxel with docetaxel alone in patients with previously treated advanced NSCLC also revealed an encouraging ORR (58.3% versus 23.1%) and PFS (6.8 versus 3.5 mo) in the subgroup of patients with EGFR mutations.14Arrieta O. Barrón F. Ramírez-Tirado L.A. et al.Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial.JAMA Oncol. 2020; 6: 856-864Crossref PubMed Scopus (30) Google Scholar Nowadays, more and more ICI-based combination trials are being developed in dedicated EGFR-mutant NSCLC patient populations. Recently, a prospective phase 2 study of toripalimab combined with chemotherapy revealed the antitumor activity in patients with EGFR-mutant advanced NSCLC who failed to previous EGFR TKI therapy, with an ORR of 50% and a median PFS of 7.0 months.15Ren S. Zhang J. Zhao Y. et al.A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: efficacy and biomarker analysis.J Clin Oncol. 2020; 38 (e21618–e21618)Google Scholar Ongoing phase 3 studies are further evaluating the efﬁcacy of ICIs in combination with chemotherapy in patients with EGFR mutations after failure on EGFR TKI treatment (CheckMate-722 [NCT02864251], KEYNOTE-789 [NCT03515837], TREASURE [NCT03924050]). Actually, data from the Flatiron Health-Foundation Medicine clinico-genomic database suggested that 27% of patients after osimertinib discontinuation have been already treated with ICIs combined with chemotherapy,16Janne P.A. Lee J.K. Madison R. et al.Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP).J Clin Oncol. 2021; 39 (9101–9101)Google Scholar reflecting the fact that we are not satisfied with the efficacy of chemotherapy alone as a salvage therapeutic approach. Although extensive research has revealed that EGFR signaling contributes to establish an immunosuppressive and uninflamed tumor microenvironment (TME),17Kumagai S. Koyama S. Nishikawa H. Antitumour immunity regulated by aberrant ERBB family signalling.Nat Rev Cancer. 2021; 21: 181-197Crossref PubMed Scopus (18) Google Scholar several key issues should be considered. First, types of EGFR mutations (L858R or 19DEL, T790M or uncommon mutations) might have distinct TME and diverse responses to ICI treatment.5Hastings K. Yu H.A. Wei W. et al.EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.Ann Oncol. 2019; 30: 1311-1320Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar,18Chen K. Cheng G. Zhang F. et al.PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.Lung Cancer. 2020; 142: 98-105Abstract Full Text Full Text PDF PubMed Scopus (19) Google Scholar,19Haratani K. Hayashi H. Tanaka T. et al.Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.Ann Oncol. 2017; 28: 1532-1539Abstract Full Text Full Text PDF PubMed Scopus (168) Google Scholar For instance, subpopulations of patients with EGFR-mutant NSCLC with EGFR L858R mutations, G719 mutations, or T790M-negative tumors have a favorable TME and may derive clinical benefits from ICI treatment.5Hastings K. Yu H.A. Wei W. et al.EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.Ann Oncol. 2019; 30: 1311-1320Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar,18Chen K. Cheng G. Zhang F. et al.PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.Lung Cancer. 2020; 142: 98-105Abstract Full Text Full Text PDF PubMed Scopus (19) Google Scholar,19Haratani K. Hayashi H. Tanaka T. et al.Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.Ann Oncol. 2017; 28: 1532-1539Abstract Full Text Full Text PDF PubMed Scopus (168) Google Scholar Second, in addition to intrinsic EGFR signaling, EGFR TKI treatment has a significant impact on TME plasticity.20Isomoto K. Haratani K. Hayashi H. et al.Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer.Clin Cancer Res. 2020; 26: 2037-2046Crossref PubMed Scopus (52) Google Scholar EGFR TKIs could increase infiltration of CD8+ T cells, dendritic cells, and M1 tumor-associated macrophages and inhibit regulatory T cell infiltration.21Jia Y. Li X. Jiang T. et al.EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: implications for combination therapies.Int J Cancer. 2019; 145: 1432-1444Crossref PubMed Scopus (50) Google Scholar,22Sugiyama E. Togashi Y. Takeuchi Y. et al.Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer.Sci Immunol. 2020; 5eaav3937Crossref PubMed Scopus (46) Google Scholar EGFR TKIs also trigger an adaptive response by means of up-regulation of type I interferons in lung cancer.23Gong K. Guo G. Panchani N. et al.EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer.Nat Cancer. 2020; 1: 394-409Crossref PubMed Scopus (17) Google Scholar,24Liu Z. Han C. Dong C. et al.Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity.Sci Immunol. 2019; 4eaav6473Crossref PubMed Scopus (15) Google Scholar Third, more complicatedly, the TME of EGFR-mutant tumors may evolve on EGFR TKI exposure21Jia Y. Li X. Jiang T. et al.EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: implications for combination therapies.Int J Cancer. 2019; 145: 1432-1444Crossref PubMed Scopus (50) Google Scholar,25Dominguez C. Tsang K.Y. Palena C. Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.Cell Death Dis. 2016; 7e2380Crossref PubMed Scopus (23) Google Scholar (Fig. 1). Intriguingly, longitudinal single-cell RNA sequencing analysis of EGFR-mutant NSCLC tumor samples revealed that EGFR TKIs could shape TME during the treatment course.26Maynard A. McCoach C.E. Rotow J.K. et al.Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing.Cell. 2020; 182: 1232-1251.e22Abstract Full Text Full Text PDF PubMed Scopus (77) Google Scholar When EGFR TKI treatment was effective (residual disease state), an inflamed TME with more CD8+ T cell infiltration and less macrophage infiltration was observed than before or failure on EGFR TKI treatment. Meanwhile, when disease progressed, indoleamine-2,3-dioxygenase-1+ macrophages, regulatory T cells, and other immunosuppressive T cell populations were enriched. Therefore, the residual disease state, characterized by an inflamed TME, may offer a window of opportunity to introduce more effective ICI treatment. Finally, chemotherapy or chemoradiotherapy is also able to influence the TME.27He Y. Chen L. Zhao L. et al.Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.Theranostics. 2021; 11: 7092-7109Crossref PubMed Scopus (2) Google Scholar,28Choe E.A. Cha Y.J. Kim J.H. et al.Dynamic changes in PD-L1 expression and CD8(+) T cell infiltration in non-small cell lung cancer following chemoradiation therapy.Lung Cancer. 2019; 136: 30-36Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar Therefore, as EGFR TKI is still the optimal first-line choice, it is crucial to evaluate the TME after exposure to EGFR TKIs, not before EGFR TKIs or exposure to other treatments, to help optimize and develop rationale ICI combinations in EGFR-mutant NSCLC. Side effect is another concern during cancer management. Unlike the toxicity proﬁles of classical chemotherapy, immune-related adverse events (irAEs) may occur in wide ranges of organs, as consequences of nonspeciﬁc and excessive activation of the immune system. Although early attempts of combining EGFR TKIs with ICIs have resulted in disconcerting safety signals, including increased risk of interstitial lung disease29Yang J.C. Shepherd F.A. Kim D.W. et al.Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report.J Thorac Oncol. 2019; 14: 933-939Abstract Full Text Full Text PDF PubMed Scopus (75) Google Scholar and liver toxicity,30Yang J.C. Gadgeel S.M. Sequist L.V. et al.Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation.J Thorac Oncol. 2019; 14: 553-559Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar ICI either as monotherapy or in combination with chemotherapy was generally well tolerated in patients with EGFR-mutant NSCLC.9Garassino M.C. Cho B.C. Kim J.H. et al.Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Lancet Oncol. 2018; 19: 521-536Abstract Full Text Full Text PDF PubMed Scopus (306) Google Scholar,12Reck M. Mok T.S.K. Nishio M. et al.Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.Lancet Respir Med. 2019; 7: 387-401Abstract Full Text Full Text PDF PubMed Scopus (368) Google Scholar The safety profiles of ICIs in patients with EGFR-mutant NSCLC were consistent with those in patients with EGFR wild-type NSCLC, and irAEs were manageable with standard treatment guidelines.9Garassino M.C. Cho B.C. Kim J.H. et al.Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Lancet Oncol. 2018; 19: 521-536Abstract Full Text Full Text PDF PubMed Scopus (306) Google Scholar Recent study revealed that the treatment sequence of ICIs and EGFR TKIs also had a significant impact on the occurrence of irAEs.31Schoenfeld A.J. Arbour K.C. Rizvi H. et al.Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.Ann Oncol. 2019; 30: 839-844Abstract Full Text Full Text PDF PubMed Scopus (110) Google Scholar Interestingly, ICIs followed by osimertinib were associated with high frequency of severe irAEs (14.6%, 6 of 41) and no irAEs occurred among patients treated with osimertinib or other EGFR TKIs followed by ICIs. In this interim, switching to ICI-based combinations after failure on EGFR TKIs is a safe choice. Hyperprogressive disease (HPD), which was characterized by an acceleration of tumor growth kinetics (tumor growth kinase ≥ 2 or time to treatment failure ≤ 2 mo), may also arise concerns during ICI treatment in patients with EGFR-mutant NSCLC because a retrospective study found that EGFR mutations were associated with increased risk of HPD.32Kato S. Goodman A. Walavalkar V. Barkauskas D.A. Sharabi A. Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate.Clin Cancer Res. 2017; 23: 4242-4250Crossref PubMed Scopus (490) Google Scholar A recent study also revealed that nivolumab boosted tumor growth by means of antibody–Fc and FcR interaction on M2 tumor-associated macrophages in EGFR-mutant patient-derived xenografts.33Lo Russo G. Moro M. Sommariva M. et al.Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade.Clin Cancer Res. 2019; 25: 989-999Crossref PubMed Scopus (199) Google Scholar Nevertheless, whether this phenomenon is a causal relationship between EGFR mutations and HPD or just reflecting the intrinsic resistance character of EGFR-mutant tumors to ICI monotherapy needs further investigation. Furthermore, subsequent larger sample studies failed to reveal a positive correlation between EGFR mutations and the incidence of HPD.34Kim C.G. Kim K.H. Pyo K.H. et al.Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.Ann Oncol. 2019; 30: 1104-1113Abstract Full Text Full Text PDF PubMed Scopus (115) Google Scholar, 35Ferrara R. Mezquita L. Texier M. et al.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy.JAMA Oncol. 2018; 4: 1543-1552Crossref PubMed Scopus (368) Google Scholar, 36Kim Y. Kim C.H. Lee H.Y. et al.Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor.J Thorac Oncol. 2019; 14: 1608-1618Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar Notably, in contrast to ICI monotherapy,37Mok T.S.K. Wu Y.L. Kudaba I. et al.Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.Lancet. 2019; 393: 1819-1830Abstract Full Text Full Text PDF PubMed Scopus (1162) Google Scholar no initial crossing of survival curves in both OS and PFS when ICIs were combined with chemotherapy suggested that the addition of chemotherapy to ICIs may avoid the occurrence of HPD.11Gadgeel S. Rodríguez-Abreu D. Speranza G. et al.Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer.J Clin Oncol. 2020; 38: 1505-1517Crossref PubMed Scopus (242) Google Scholar Interestingly, a recent study verified that the incidence of HPD was significantly lower in patients with advanced NSCLC treated with ICIs combined with chemotherapy than those treated with ICI monotherapy (2.9% versus 17.6%).38Matsuo N. Azuma K. Kojima T. et al.Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.Investig New Drugs. 2021; 39: 1150-1158Crossref PubMed Scopus (1) Google Scholar Therefore, HPD may also not be a problem in patients with EGFR-mutant NSCLC during ICI treatment, especially with the addition of cytotoxic chemotherapy. Taken together, in our opinion, it is still too early to draw the final conclusion that EGFR-mutant NSCLC is the restricted zone for ICI treatment. In fact, our attempts to improve the poor prognosis of patients with EGFR-mutant NSCLC after failure on all available TKIs by means of novel cancer immunotherapy are always underway.39Shi M. Chen J. Li K. et al.SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with EGFR mutations: data from a multicenter phase 1 study.J Clin Oncol. 2021; 39 (9055–9055)Google Scholar,40Bendell J.C. LoRusso P. Overman M.J. et al.Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).J Clin Oncol. 2021; 39 (9047–9047)Google Scholar If one therapeutic approach, here we mean ICIs combined with chemotherapy, has revealed promising efficacy, without extra toxicity and unpredictable risk, why do we not consider it? We would rather feel regret after trying our best than giving up an opportunity, which may bring long-term survival to our patients. Fei Zhou: Conceptualization, Investigation, Writing—Original draft preparation, Funding acquisition. Caicun Zhou: Conceptualization, Investigation, Writing—Reviewing and editing, Funding acquisition. The authors thank Drs. Fengying Wu and Meng Qiao for all their constructive comments and advice. This study was supported in part by grants from the Shanghai “Rising Stars of Medical Talent” Youth Development Program and Shanghai Innovative Collaboration Project (number 2020CXJQ02). Combination Chemotherapy Alone Should Be Used in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase InhibitorsJournal of Thoracic OncologyVol. 16Issue 10PreviewThe discovery of the driver gene EGFR and the precision treatment of this target have been a revolution in the treatment of NSCLC. The EGFR tyrosine kinase inhibitor (TKI), osimertinib, has become a standard treatment for patients with advanced or resected NSCLC harboring EGFR mutations. In the FLAURA study, osimertinib was administered as first-line treatment in advanced disease, and compared with first-generation drugs, it significantly improved the duration of response (from 8.5 to 17.2 mo), progression-free survival (from 10.2 to 18.9 mo), and overall survival (OS) (from 31.8 to 38.6 mo). Full-Text PDF

Treatment of Nivolumab Results in Hyperprogressive Disease in a Patient Harboring EGFR Exon 20 Insertion and MYC Amplification

Characterization of Hyperprogression after Immunotherapy in a Lung Adenocarcinoma Patient with Strong Expression of Programmed Death Ligand 1.

Extremely High Infiltration of CD8+PD-L1+ Cells Detected in a Stage III Non-Small Cell Lung Cancer Patient Exhibiting Hyperprogression During Anti-Pd-l1 Immunotherapy after Chemoradiation: A Case Report.

Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody

Abstract 5200: The incidence and risk factors of hyperprogressive disease(HPD) in non-small cell lung cancer(NSCLC) treated with immune checkpoint inhibitors(ICI)

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

Response to Nivolumab As Salvage Therapy in a Patient with Thymic Carcinoma

Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer

Chemotherapy Should Be Combined with Checkpoint Inhibitors in the Treatment of Patients with Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature

Abstract 3548: Role of the cancer cell proteome and tumor microenvironment in the hyperprogression (HP) phenotype response to immune checkpoint blockade

Hyperprogressive Disease in Cervical Small Cell Carcinoma Treated by Immune Checkpoint Inhibitor

Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy

Clinical implication of multiplex IHC and serologic biomarkers on hyperprogression in NSCLC patients receiving immune checkpoint blockers in real world

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review

Case Report: Tumor Microenvironment Characteristics in a Patient with HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease.

Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors